ArticleOncotarget2017
Circulating tumor cells: potential markers of minimal residual disease in ovarian cancer? a study of the OVCAD consortium.
Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 50 citations in OpenAlex.
- Phenotypic and genotypic characterization of single circulating tumor cells in the follow-up of high-grade serous ovarian cancer.Molecular oncology · 2026Article
- Pre-operative circulating tumor cells predict worse treatment outcome in patients with high-grade serous ovarian cancer.Oncogene · 2026Article
- Multi-cancer detection of circulating tumor cells by targeting oncofetal chondroitin sulfate.NPJ precision oncology · 2025Article
- Case Report: Blood single-cell analysis of a IVB high-grade serous ovarian cancer patient presenting a favorable prognosis.Frontiers in oncology · 2025Article
- Insights into the role of MSLN-positive circulating tumor cell as an auxiliary diagnostic biomarker in epithelial ovarian cancer.Frontiers in oncology · 2025Article
- Review
- CXCL12-loaded-hydrogel (CLG): A new device for metastatic circulating tumor cells (CTCs) capturing and characterization.Heliyon · 2024Article
- Review
- Diagnostic biomarkers in ovarian cancer: advances beyond CA125 and HE4.Therapeutic advances in medical oncology · 2024Review
- Diagnostic value of liquid biopsy in the era of precision medicine: 10 years of clinical evidence in cancer.Exploration of targeted anti-tumor therapy · 2023Review
- Liquid biopsy in ovarian cancer in China and the world: current status and future perspectives.Frontiers in oncology · 2023Review
- Detection and Characterization of Circulating Tumor Cells Using Imaging Flow Cytometry-A Perspective Study.Cancers · 2022Article
- Detection ofCancers · 2022Article
- Detection of circulating tumor cells and evaluation of epithelial-mesenchymal transition patterns of circulating tumor cells in ovarian cancer.Translational cancer research · 2022Article
- Potential clinical utility of liquid biopsies in ovarian cancer.Molecular cancer · 2022Review
- Establishment of an optimized CTC detection model consisting of EpCAM, MUC1 and WT1 in epithelial ovarian cancer and its correlation with clinical characteristics.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2022Article
- A meta-analysis of the prognostic value of circulating tumor cells in ovarian cancer.American journal of translational research · 2022Review
- Article
- The Long-Term Prognostic Significance of Circulating Tumor Cells in Ovarian Cancer-A Study of the OVCAD Consortium.Cancers · 2021Article
- Liquid Biopsy in the Clinical Management of High-Grade Serous Epithelial Ovarian Cancer-Current Use and Future Opportunities.Cancers · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 8 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIn 75% of ovarian cancer patients the tumor mass is completely eradicated by established surgical and cytotoxic treatment; however, the majority of the tumors recur within 24 months. Here we investigated the role of circulating tumor cells (CTCs) indicating occult tumor load, which remains inaccessible by established diagnostics. EXPERIMENTAL
designBlood was taken at diagnosis (baseline samples,
resultsCTCs were observed in 26.5% baseline and 7.7% follow-up blood samples at a mean number of 12.4 and 2.8 CTCs per ml blood, respectively. Baseline CTCs indicated a higher risk of death in R0 patients with complete gross resection (univariate: HR 2.158, 95% CI 1.111-4.191,
conclusionsOur data suggest that CTCs detected by the multi-marker protein panel and/or MECOM/HHLA1 FISH represent minimal residual disease in optimally debulked ovarian cancer patients. The role of CTCs cells especially for clinical therapy stratification of the patients has to be validated in consecutive larger studies applying standardized treatment schemes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.